FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2970033439> ?p ?o ?g. }

• W2970033439 endingPage "66" @default.
• W2970033439 startingPage "61" @default.
• W2970033439 abstract "Background: Up to 44% of patients treated with infliximab and 7% of patients treated with etanercept reported to have anti-drug antibodies within the first 6 months of treatment. Recently, anti-TNF-α therapies have been reported to be employed in the induction of the druginduced lupus erythematous. Objective: The aim of the present study was to investigate the relationship between anti-TNFα antibodies and various manifestations of lupus erythematous. Methods: We enrolled a total of 56 cases divided into 28 known cases of rheumatoid arthritis and 28 cases of ankylosing spondylitis patients and 56 controls. The case group was divided into 4 groups according to the underlying disease (RA or AS) and treatment regimen (infliximab or etanercept). ANA and anti-dsDNA levels and lupus criteria were assessed at the beginning of the study and 4 months after the initiation of anti-TNFα. Results: 36% and 21% of RA patients treated with infliximab, were ANA and anti-dsDNA positive after 4 months (P=0.003, P=0.025). 28% and 7% of RA patients treated with etanercept, were ANA and anti-dsDNA positive after 4 months (P=0.009, P=0.15). 21% and 7% of AS patients treated with infliximab, were ANA and anti-dsDNA positive, respectively (P=0.025, P=0.15). 14% and 7% of AS patients treated with etanercept, were ANA and anti-dsDNA positive, respectively (P=0.63, P=0.15). Three patients who were positive for auto-antibodies developed three criteria for SLE. Conclusions: Infliximab potentially may increase both ANA and anti-dsDNA levels in rheumatoid arthritis, but only ANA in ankylosing spondylitis patients. In general, clinicians should consider different clinical symptoms of ATIL, which may be present as a lupus-like syndrome similar to idiopathic SLE or classical DIL." @default.
• W2970033439 created "2019-09-05" @default.
• W2970033439 creator A5059469088 @default.
• W2970033439 creator A5063250164 @default.
• W2970033439 creator A5065058000 @default.
• W2970033439 date "2020-03-05" @default.
• W2970033439 modified "2023-10-17" @default.
• W2970033439 title "Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept" @default.
• W2970033439 cites W1518420099 @default.
• W2970033439 cites W1972307658 @default.
• W2970033439 cites W1973123086 @default.
• W2970033439 cites W1992628263 @default.
• W2970033439 cites W1999767041 @default.
• W2970033439 cites W2000905503 @default.
• W2970033439 cites W2006427242 @default.
• W2970033439 cites W2027497238 @default.
• W2970033439 cites W2029993898 @default.
• W2970033439 cites W2078744808 @default.
• W2970033439 cites W2097998028 @default.
• W2970033439 cites W2103874459 @default.
• W2970033439 cites W2104125890 @default.
• W2970033439 cites W2109172918 @default.
• W2970033439 cites W2110826367 @default.
• W2970033439 cites W2111913995 @default.
• W2970033439 cites W2128775174 @default.
• W2970033439 cites W2128952811 @default.
• W2970033439 cites W2142004396 @default.
• W2970033439 cites W2146203649 @default.
• W2970033439 cites W2148006860 @default.
• W2970033439 cites W2154362046 @default.
• W2970033439 cites W2159860161 @default.
• W2970033439 cites W2163912950 @default.
• W2970033439 cites W2166771071 @default.
• W2970033439 cites W2174322658 @default.
• W2970033439 cites W2177368405 @default.
• W2970033439 cites W2205391572 @default.
• W2970033439 cites W2335495110 @default.
• W2970033439 cites W2336588424 @default.
• W2970033439 cites W2415839216 @default.
• W2970033439 cites W2528907432 @default.
• W2970033439 cites W2608850138 @default.
• W2970033439 cites W2734764199 @default.
• W2970033439 cites W2754846891 @default.
• W2970033439 cites W2791302651 @default.
• W2970033439 cites W2883282429 @default.
• W2970033439 cites W4211019157 @default.
• W2970033439 cites W4211203343 @default.
• W2970033439 doi "https://doi.org/10.2174/1573397115666190506152729" @default.
• W2970033439 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31057111" @default.
• W2970033439 hasPublicationYear "2020" @default.
• W2970033439 type Work @default.
• W2970033439 sameAs 2970033439 @default.
• W2970033439 citedByCount "9" @default.
• W2970033439 countsByYear W29700334392020 @default.
• W2970033439 countsByYear W29700334392021 @default.
• W2970033439 countsByYear W29700334392022 @default.
• W2970033439 countsByYear W29700334392023 @default.
• W2970033439 crossrefType "journal-article" @default.
• W2970033439 hasAuthorship W2970033439A5059469088 @default.
• W2970033439 hasAuthorship W2970033439A5063250164 @default.
• W2970033439 hasAuthorship W2970033439A5065058000 @default.
• W2970033439 hasConcept C126322002 @default.
• W2970033439 hasConcept C149443304 @default.
• W2970033439 hasConcept C159654299 @default.
• W2970033439 hasConcept C163764329 @default.
• W2970033439 hasConcept C17991360 @default.
• W2970033439 hasConcept C198451711 @default.
• W2970033439 hasConcept C203014093 @default.
• W2970033439 hasConcept C2776912625 @default.
• W2970033439 hasConcept C2777077863 @default.
• W2970033439 hasConcept C2777138892 @default.
• W2970033439 hasConcept C2777226972 @default.
• W2970033439 hasConcept C2777402515 @default.
• W2970033439 hasConcept C2777575956 @default.
• W2970033439 hasConcept C2779134260 @default.
• W2970033439 hasConcept C2779650986 @default.
• W2970033439 hasConcept C2780132546 @default.
• W2970033439 hasConcept C71924100 @default.
• W2970033439 hasConcept C90924648 @default.
• W2970033439 hasConceptScore W2970033439C126322002 @default.
• W2970033439 hasConceptScore W2970033439C149443304 @default.
• W2970033439 hasConceptScore W2970033439C159654299 @default.
• W2970033439 hasConceptScore W2970033439C163764329 @default.
• W2970033439 hasConceptScore W2970033439C17991360 @default.
• W2970033439 hasConceptScore W2970033439C198451711 @default.
• W2970033439 hasConceptScore W2970033439C203014093 @default.
• W2970033439 hasConceptScore W2970033439C2776912625 @default.
• W2970033439 hasConceptScore W2970033439C2777077863 @default.
• W2970033439 hasConceptScore W2970033439C2777138892 @default.
• W2970033439 hasConceptScore W2970033439C2777226972 @default.
• W2970033439 hasConceptScore W2970033439C2777402515 @default.
• W2970033439 hasConceptScore W2970033439C2777575956 @default.
• W2970033439 hasConceptScore W2970033439C2779134260 @default.
• W2970033439 hasConceptScore W2970033439C2779650986 @default.
• W2970033439 hasConceptScore W2970033439C2780132546 @default.
• W2970033439 hasConceptScore W2970033439C71924100 @default.
• W2970033439 hasConceptScore W2970033439C90924648 @default.
• W2970033439 hasIssue "1" @default.

• next